Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations

Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful

(2012) Maialen Martin-Arruti et al.   HISTOPATHOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

(2012) Hiroki Nakajima et al.   Breast Cancer

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer

(2011) Abderrahim El Guerrab et al.   PLoS One

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

(2010) E. J. Macaskill et al.   BREAST CANCER RESEARCH AND TREATMENT

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

EGFR expression and gene copy number in triple-negative breast carcinoma

(2010) Berrak Gumuskaya et al.   CANCER GENETICS AND CYTOGENETICS

Extrachromosomal amplification mechanisms in a glioma with amplified sequences from multiple chromosome loci

(2010) Anne Gibaud et al.   HUMAN MOLECULAR GENETICS

Characteristics of triple-negative breast cancer

(2010) Tim C. de Ruijter et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Gene amplification, radiation sensitivity and DNA double-strand breaks

(2010) Chiara Mondello et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Relationships Linking Amplification Level to Gene Over-Expression in Gliomas

(2010) Nicolas Vogt et al.   PLoS One

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

ISO 15189 accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory II

(2009) Gulderen Yanikkaya-Demirel   CLINICAL BIOCHEMISTRY

ISO 15189 Accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory I

(2009) Omer Guzel et al.   CLINICAL BIOCHEMISTRY

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas

(2009) Charpin   INTERNATIONAL JOURNAL OF ONCOLOGY

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

(2009) Aye Aye Thike et al.   MODERN PATHOLOGY

Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers

(2009) E. Lin et al.   MOLECULAR CANCER RESEARCH

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays

(2008) Colette Charpin et al.   INTERNATIONAL JOURNAL OF CANCER